Background: The 19 kDa C-terminal region of the merozoite surface protein 1 (MSP1 19) has been suggested as candidate for part of a subunit vaccine against malaria. A major concern in vaccine development is the polymorphism observed in different plasmodial strains. The present study examined the extension and immunological relevance of the allelic polymorphism of the MSP119 from Plasmodium vivax, a major human malaria parasite. Materials and Methods: We cloned and sequenced 88 gene fragments representing the MSP19 from 28 Brazilian isolates of P. vivax. Subsequently, we evaluated the
Introduction
Malaria remains the most prevalent and devastating parasitic disease worldwide, with a yearly estimate of more than 300 million cases due to Plasmodium falciparum and at least 40 million cases due to P. vivax. The population at risk is estimated at billions of individuals living in tropical regions of the world. The disease is most prevalent and deadly in Africa, where P. falciparum is endemic. Although the patterns of disease transmission, infection, and mortality are quite diverse, malaria transmission also occurs in large areas of South and Southeast Asia, Latin Amer-ica, and Oceania, where malaria caused by P. vivax is widespread.
Although malaria control was successful in many countries in the past, it is now very difficult to eradicate the disease in developing countries, mainly because of the presence of drugresistant parasites and mosquito vectors. In view of these problems, the development of new strategies for prevention and control of the disease are in great need.
Mass vaccination is considered a feasible objective that in the future may be added to other strategies such as chemotherapy, vector control, etc., for the prevention and control of malaria. One of the most promising vaccine candidates against the erythrocytic forms of malaria is the merozoite surface protein 1 (MSP1, reviewed in ref. 1 ). This protein is synthesized as a largemolecular-weight precursor (180-230 kDa) during schizogony and is later processed into several smaller fragments corresponding to the major merozoite surface proteins. During the invasion process, a proteolytic cleavage step releases most of the molecule from the merozoite membrane and only a 19 kDa glycerolphosphatidylinositolanchored fragment of the C-terminus (MSP119) is carried into the invaded red cells (2, 3) . The biological importance of MSP1 for parasite survival is unknown; however, it is well established that antibodies that recognize its C-terminal region inhibit merozoite invasion in vitro (3) (4) (5) and confer passive immunity on naive mice (6, 7) . Most relevant to malaria control is the fact that immunization with recombinant proteins based on the sequence of MSP119 in human, non-human primate, and rodent species malaria can provide remarkable protection against experimental infection with blood stages of Plasmodium (8) (9) (10) (11) (12) (13) .
MSPI19 of different species consists of two domains, each with six cysteine residues configured as an epidermal growth factor (EGF)-like domain. EGF-like structures are immunogenically very important. Epitopes recognized by protective antibodies are dependent on the conformation provided by the disulfide bonds and the presence of both EGF-like domains (9, 14) .
Despite the structural conservation, there are several amino acid modifications among MSP119 of different species of malaria. Most relevant for vaccine development is the polymorphism observed in different strains of the same species. A series of amino acid substitutions were detected in the MSP1 9 gene of P. yoelii, a rodent malaria parasite (15) . These substitutions are immunologically relevant because protective antibodies generated by vaccination are directed at these polymorphic epitopes (16 (26, 27) . This high frequency of responders to PvMSP119 was also described in an independent survey performed in an area of P. vivax transmission in New Guinea (28) . The fact that more than 70% of the individuals had IgG antibodies suggests that PvMSP 119 is highly conserved among the different isolates of P. vivax. Nevertheless, some individuals fall to develop antibodies to PvMSPl19 even in the presence of high antibody titers to other polypeptides of PvMSPI (26, 27) .
The lack of reactivity observed in some individuals could be explained at least in part by allelic variation. Given this possibility, the present study was designed to examine the extent of PvMSP 19 Soares et al. (26, 27) . Eighteen additional blood samples were collected at the Tropical Medical Center (CEMETRON), Porto Velho, state of Rond6nia, in the northwest part of Brazil. Five milliliters of peripheral blood were collected from each patient directly into EDTA tubes before drug treatment. Plasma and infected erythrocytes were removed after centrifugation, stored frozen at -200C, and transported to Sao Paulo for further study.
Cloning of PCR Products and Sequencing Genomic DNA was purified from infected blood samples as described earlier (32) . Briefly, 1 ml of TE (10 mM Tris-HCl, pH 7.4, and 1 mM EDTA, pH 8.0) was added to each blood sample. After centrifugation at 12,500 x g for 10 sec, the pellet was resuspended a second time in TE, and the procedure was repeated twice. The colorless pellets were resuspended in 200 also performed using a cloned PvMSP119 sequence as the PCR template. The PCR products were separated on agarose gel. The 314 bp band was excised from the gel and the DNA purified with glass beads of a commercially available kit (Nucleiclean, Sigma) according to the specifications of the manufacturer. The DNA concentration was estimated in agarose gel. PCR products were cloned directly using a commercially prepared cloning plasmid with a single T-base overhang (pMOS Blue, Amersham). Eighty-eight amplified gene fragments cloned from 28 isolates were selected for sequencing studies. Two to four plasmids were sequenced from each isolate. Before sequencing, all 88 plasmids were checked for the presence of an insert that hybridized by Southern blot with a radiolabeled DNA representing the PvMSPl 19 (Belem strain). Nucleotide sequence analysis was done with the thermosequenase cycle sequencing kit (Amersham) according to the manufacturer's instructions. Plasmid-specific primers (M13 Universal and T7) were labeled with [y_32P] ATP (Amersham) using T4 polynucleotide kinase (Life Technologies).
Generation of Plasmids Coding for GST-Fusion
Proteins Representing Allelic Forms of PvMSPI 9 A recombinant protein containing amino acids 1615 to 1704 of PvMSP119 (Belem strain) was generated. The C-terminal region of PvMSPI was amplified by PCR, using the cloned PvMSP 119 (26) sequence as a substrate for primers: 5' -GGGATCCCCACTATGAGCTC-CGAGCAC -3' (forward) and 5' -TGAATTC -CCGCTACAGAAAACTCCCTCAAA-3' (reverse). The amplified fragment was purified and cloned into the pMOS Blue T-vector, and both strands were sequenced as described above. The insert was removed by treatment with BamHI and EcoRI and ligated into the pGEX-3X expression vector (Pharmacia) treated with these same enzymes. The recombinant GST-PvMSP1I9 differs from the recombinant protein ICB10 (26) in that it does not contain the amino acids that are most likely to be removed for insertion of the glycerolphosphatidylinositol anchor. This recombinant protein presented a much better solubility and improved yield for purification.
The coding sequence of PvMSP119 (Belem strain) was modified by PCR mutagenesis as follows: a single substitution was introduced, a G for an A (nt 5050), resulting in an amino acid change from Lys1684 to Glu1684 substitution toward the C-terminal of the second epidermal growth factor (EGF) domain. Two PCR amplifications were performed using the following oligonucleotide primers: (i) 5' -GGGATCCCCAC-TATGAGCTCCGAGCAC-3' (forward) and 5'-AGACGATTlCATrGCTGTCC-3' (reverse); (ii) 5' -GGACAGCAATGAAATCGTCT-3' (forward) and 5'-TGAATTCCCGCTACAGAAAACTCCCT-CAAA-3' (reverse). Products of these two PCR amplifications were purified on agarose gel and used as targets for a second amplification. The primers for the amplification were 5'-GGGATC-CCCACTATGAGCTCCGAGCAC-3' (forward) and 5' -TGAATTC CC GCTACAGAAAACTC C CT-CAAA-3' (reverse). The product of this PCR reaction (1615Thr to 1704Ser) was purified and cloned into the pMOS Blue T-vector and both strands were sequenced to confirm the single base pair mutation. The insert corresponding to the PCR product was excised by treatment with BamHI and EcoRl and ligated into the pGEX-3X expression vector treated with these same enzymes.
The DNA representing the PvMSP119 fragments of Belem and Asian strains were removed from the pGEX plasmid by treatment with the restriction enzymes Msd and Pstl. This DNA fragment was purified and ligated in the presence of dNTPs and Klenow polymerase into the yeast expression plasmid pEG(KT) (34) (26, 27) . Briefly, microtiter plates (Costar, Cambridge, MA) were coated with 200 ng/well of affinity-purified bacterial fusion proteins or GST. Because of restrictions in the amount of yeast-derived recombinant proteins, we used 100 ng/well of these fusion proteins or GST. Human plasma samples were added to wells at 1:200 dilution with subsequent 2-fold serial dilutions until 1:102,400 was attained. Rabbit and mouse serum samples were also tested at the indicated dilutions. After 2 hr incubation at room temperature, unbound material was washed away, and peroxidase-conjugated goat anti-human IgG (Fc-specific, 1:10,000) (Sigma), or anti-rabbit IgG or anti-mouse IgG (both diluted 1:4000, from Kirkegaard and Perry, Gaithersburg, MD) was added to each well. After 1 hr incubation at room temperature, excess labeled antibody was removed during washing, and the reaction was developed with o-phenylenediamine (Sigma). Plates were read at 492 nm on an ELISA reader (Labsystems Multiskan MS). The OD492 values in Figure 4 represent binding of IgG to the recombinant protein after subtraction of binding of the same serum to GST alone.
The inhibition assay was performed as described by Devey et al. (35) . ELISA plates were coated with the recombinant bacterial PvMSPl 1 9
representing the Belem allele. In Figure Sa, In parallel, as a control, we amplified the DNA portion coding for the highly polymorphic region P5 located in the N-terminal portion of PvMSPI (33) . According to the size of the PCR products, we found two distinct alleles described earlier in Brazilian isolates (33 Belem strain (Fig. lB, C) .
Initially, these four fusion proteins and GST were used as antigens for recognition by a murine MAb specific for PvMSP 119 (31) (29, 30) ]. Both the polyclonal antiserum and the MAb strongly inhibited the in vitro invasion of reticulocytes by P. vivax merozoites of the Belem strain (J. Barnwell, unpublished results). We found that rabbit polyclonal antibodies recognized similarly the recombinant proteins representing each allelic form of PvMSP 119 generated in E. coli ( Fig. 2A) . Comparable recognition was also observed when we used yeastderived recombinant proteins in the ELISA (Fig. 2B) . The MAb was also unable to differentiate the two allelic forms of PvMSP 119 produced either in E. coli or in yeast (Fig. 2C, D (Fig. 3) . The same results were obtained when we used bacterial (Fig. 3A , B) or yeast-derived (Fig. 3C, D (26, 27 Figure 5A . Different Figure SB 19 only recognized parasites of a homologous strain. Protective immunity against P. yoelii was also strain-specific (16) . This work suggested that similar strainspecific protective antibodies could be generated in human malaria.
Studies on the recognition of allelic forms of MSP119 of P. falciparum, a human malaria parasite, were performed with yeast-derived recombinant proteins representing four alleles (E-KNG, Q-KNG, E-TSR, and Q-TSR). They demonstrated that there are multiple conserved epitopes among these different allelic forms recognized by human and non-human primate antibodies (23, 24, (40) (41) (42) . The recognition by human antibodies of recombinant proteins representing allelic forms with a single amino acid modification (E-KNG and Q-KNG) was quite similar (23, 40) . These results resemble the findings reported here, and they may suggest that single amino acid substitutions may not be sufficient to impair recognition by antibodies. The recognition of a third allelic form (E-TSR), which has three or four amino acid modifications compared to E-KNG or Q-KNG, respectively, was not as similar, and the presence of strain-specific human antibodies was observed (23, 24, 40) . To our knowledge, no comparisons between other allelic forms found in nature have been reported thus far (19) .
Alternatively, the single amino acid substitution found in the two allelic forms of PvMSP 1I9
may represent a strategy to evade cell-mediated immune responses. It is well documented that few amino acid changes can dramatically impair the binding of peptides to MHC class I or class II (43) (44) (45) (46) . They may also reduce recognition by T cells or generate antagonistic peptides that inhibit activation of specific T cells by the MHCpeptide complex (47) (48) (49) MSP1 receptor has not been described.
In conclusion, the present findings suggest that the use of PvMSP119 as part of a subunit vaccine against P. vivax might be greatly facilitated by the limited genetic polymorphism and the predominant recognition of conserved epitopes by antibodies.
